Privia Care Center locations that do not currently conduct clinical trials will receive embedded research from Velocity.
Multi-specialty clinical sites organization Velocity Clinical Research, and Privia Health, a physician enablement company, have partnered to embed clinical research sites in Privia’s practice network.1
The partnership will integrate research sites within existing Privia Care Center locations that do not currently conduct clinical trials. Privia serves more than 3,700 providers and 4.4 million patients. Velocity will staff and operate the joint research sites, bringing management experience in clinical trial operations and patient recruitment. The first of these sites is in West Texas Health, a clinic in Abilene, Texas.
This latest partnership builds on Velocity’s December 2022 acquisition of Meridian Clinical Research, which accelerated its move into specialty care. The acquisition provided approximately 80 sites in the U.S. and Europe, and a tech hub in Hyderabad, India.2
Paul Evans, PhD, Velocity President and CEO, said in a release: “Through an embedded model, Privia benefits from increased activity at their clinics and Velocity has the opportunity to move into new therapeutic areas. We expect to see more partnerships of this kind, as the clinical trials landscape matures and achieves the scale to work with established organizations, like Privia.”
References
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
SCOPE Summit 2025: Enhancing the Patient Experience Through Site Centricity
February 12th 2025In an interview with ACT senior editor Andy Studna at SCOPE Summit, Ashley Davidson, vice president, product lead - sponsor tech strategy, Advarra, highlights the need for more site-centric approaches in study startup.